Biotech funds spring like mushrooms in Singapore

Singapore is capturing the attention of biotech fund managers who are competing for the island-state''s investors.

Toni Clarke

September 08, 2000

Singapore investors seeking to gamble on biotechnology stocks are suddenly spoilt for choice of investment vehicles.

Just two months ago there were no dedicated biotech funds in Singapore. Now there are three. First came Franklin Templeton Investments and Dresdner Asset Management. This week UBS Asset Management joined the fray with its UBS (SG) Investment Fund-Biotech. Others, such as Polaris Asset Management are also gearing up to launch Asian biotechnology funds.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Southeast Asia